Department of Cardiovascular Medicine, Faculty of Life Science, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Atherosclerosis. 2011 Jul;217(1):158-64. doi: 10.1016/j.atherosclerosis.2011.02.050. Epub 2011 Mar 10.
Coenzyme Q10 levels are low in patients with coronary artery disease (CAD), and increasing or preserving coenzyme Q10 could be a beneficial strategy. Exercise and statins improve high-density lipoprotein cholesterol (HDL-C) levels. However, statins inhibit coenzyme Q10 biosynthesis, and the combination of statins with coenzyme Q10 supplementation increases HDL-C compared to statins alone. We compared the effects of two statins (rosuvastatin and atorvastatin) combined with exercise on coenzyme Q10 and HDL-C levels in CAD patients.
After randomizing 28 CAD patients to rosuvastatin (n=14) and atorvastatin (n=14) groups, patients performed weekly in-hospital aerobic exercise and daily home exercise for 20 weeks. We measured serum lipids, ubiquinol, and exercise capacity.
Both statins equally improved exercise capacity and lowered low-density lipoprotein cholesterol and triglyceride levels. Rosuvastatin significantly increased HDL-C (rosuvastatin, +12 ± 9 mg/dL [+30%], atorvastatin, +5 ± 5 mg/dL [+13%], p=0.014) and apolipoprotein A1 (ApoA1) (rosuvastatin, +28.3 ± 20.7 mg/dL, atorvastatin, +13.4 ± 12.0 mg/dL, p=0.030) compared to atorvastatin. Atorvastatin significantly decreased serum ubiquinol (731 ± 238 to 547 ± 219 nmol/L, p=0.001), but rosuvastatin (680±233 to 668 ± 299 nmol/L, p=0.834) did not. There was a significant positive correlation between changes in ubiquinol and ApoA1 (r=0.518, p=0.005). Multivariate regression analysis showed that changes in ubiquinol correlated significantly with changes in ApoA1 after adjusting for age, sex, body mass index, and smoking (β=0.502, p=0.008).
Compared to atorvastatin, rosuvastatin combined with exercise significantly preserved ubiquinol levels associated with an increase in HDL-C. Rosuvastatin with regular exercise could be beneficial for CAD patients.
辅酶 Q10 水平在冠状动脉疾病(CAD)患者中较低,增加或保留辅酶 Q10 可能是一种有益的策略。运动和他汀类药物可提高高密度脂蛋白胆固醇(HDL-C)水平。然而,他汀类药物抑制辅酶 Q10 的生物合成,与他汀类药物单独使用相比,他汀类药物与辅酶 Q10 补充剂的联合使用可增加 HDL-C。我们比较了两种他汀类药物(瑞舒伐他汀和阿托伐他汀)联合运动对 CAD 患者辅酶 Q10 和 HDL-C 水平的影响。
将 28 例 CAD 患者随机分为瑞舒伐他汀(n=14)和阿托伐他汀(n=14)组后,患者每周在医院进行有氧运动,每天在家进行运动,共 20 周。我们测量了血清脂质、泛醇和运动能力。
两种他汀类药物均同等程度地提高了运动能力,并降低了低密度脂蛋白胆固醇和甘油三酯水平。瑞舒伐他汀可显著增加 HDL-C(瑞舒伐他汀,+12±9mg/dL[+30%],阿托伐他汀,+5±5mg/dL[+13%],p=0.014)和载脂蛋白 A1(ApoA1)(瑞舒伐他汀,+28.3±20.7mg/dL,阿托伐他汀,+13.4±12.0mg/dL,p=0.030),而阿托伐他汀则没有。阿托伐他汀可显著降低血清泛醇(731±238 至 547±219nmol/L,p=0.001),但瑞舒伐他汀(680±233 至 668±299nmol/L,p=0.834)则没有。泛醇与 ApoA1 的变化呈显著正相关(r=0.518,p=0.005)。多元回归分析显示,在调整年龄、性别、体重指数和吸烟因素后,泛醇的变化与 ApoA1 的变化显著相关(β=0.502,p=0.008)。
与阿托伐他汀相比,瑞舒伐他汀联合运动可显著保留与 HDL-C 增加相关的泛醇水平。瑞舒伐他汀结合规律运动可能对 CAD 患者有益。